Literature DB >> 6233934

Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.

C U Tuazon, H Miller.   

Abstract

The activity of teichomycin A2 was compared with that of vancomycin in vitro against clinical isolates of staphylococci and enterococci. Teichomycin A2 was more active than vancomycin active against all isolates tested. Synergistic studies also demonstrated that teichomycin A2 combined with rifampin is more active than vancomycin combined with rifampin against Staphylococcus aureus and Staphylococcus epidermidis isolates. Teichomycin A2, either singly or in combination with an aminoglycoside, was more active against Streptococcus faecalis isolates.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233934      PMCID: PMC185541          DOI: 10.1128/AAC.25.4.411

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin.

Authors:  V T Andriole
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

2.  Serial dilution antibiotic sensitivity testing with the microtitrator system.

Authors:  J H Marymont; R M Wentz
Journal:  Am J Clin Pathol       Date:  1966-05       Impact factor: 2.493

3.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital.

Authors:  J E Peacock; F J Marsik; R P Wenzel
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

5.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties.

Authors:  F Parenti; G Beretta; M Berti; V Arioli
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

Review 6.  Vancomycin revisited.

Authors:  F V Cook; W E Farrar
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

7.  Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis.

Authors:  G D Christensen; A L Bisno; J T Parisi; B McLaughlin; M G Hester; R W Luther
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

8.  Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak.

Authors:  L D Saravolatz; N Markowitz; L Arking; D Pohlod; E Fisher
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

9.  Vancomycin therapy of bacterial endocarditis.

Authors:  E W Hook; W D Johnson
Journal:  Am J Med       Date:  1978-09       Impact factor: 4.965

10.  In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.

Authors:  P E Varaldo; E Debbia; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

View more
  12 in total

1.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

2.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

3.  Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.

Authors:  A M Mackenzie; N E Macdonald
Journal:  Can J Infect Dis       Date:  1990

4.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.

Authors:  G P Voorn; J Kuyvenhoven; W H Goessens; W C Schmal-Bauer; P H Broeders; J Thompson; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine.

Authors:  A Pantosti; I Luzzi; R Cardines; P Gianfrilli
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.

Authors:  K E Aldridge; A Janney; C V Sanders
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

9.  Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.

Authors:  C Leport; C Perronne; P Massip; P Canton; P Leclercq; E Bernard; P Lutun; J J Garaud; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.